QUANTITATION OF DIFFERENTIAL SENSITIVITY OF HUMAN-TUMOR STEM-CELLS TO ANTI-CANCER DRUGS
QUANTITATION OF DIFFERENTIAL SENSITIVITY OF HUMAN-TUMOR STEM-CELLS TO ANTI-CANCER DRUGS
复制标题
DOI：
10.1056/nejm197806152982401
复制
发表时间：
1978-01-01
影响因子：
158.5
通讯作者：
MOON, TE
中科院分区：
文献类型：
--
作者：
SALMON, SE;HAMBURGER, AW;MOON, TE
采用直接体外肿瘤集落试验检测肿瘤干细胞对抗癌药物的敏感性，对9例骨髓瘤和9例卵巢癌患者进行了32项回顾性或前瞻性的临床研究。这些结果具有明显的相关性(P<；0.00001)。观察到个别患者对所测试的6种药物的敏感性和耐药性的独特模式。8例骨髓瘤和3例卵巢癌的体外药敏与体内药敏一致，1例骨髓瘤的药敏与体内药敏不一致。在骨髓瘤和卵巢癌的所有5个比较中，体外耐药与临床耐药相关。这项测试显示了足够的前景，可以保证进行更大规模的测试，以确定其在选择新药物和个体化癌症化疗方案方面的有效性。
With a direct in vitro tumor-colony assay developed to measure sensitivity of human tumor stem cells to anticancer drugs, 32 retrospective or prospective clinical studies were done in 9 patients with myeloma and 9 with ovarian cancer treated with standard agents that were tested in vitro. The results were clearly correlated (P < 0.00001). Unique patterns of sensitivity and resistance to the 6 drugs tested were observed for individual patients. In 8 cases of myeloma and 3 of ovarian carcinoma in vitro sensitivity corresponded with in vivo sensitivity whereas in 1 case of myeloma it did not. In vitro resistance correlated with clinical resistance in all 5 comparisons in myeloma and all 15 in ovarian cancer. This assay shows sufficient promise to warrant larger scale testing to determine its efficacy for selection of new agents and individualized cancer chemotherapy regimens.